Table 1.
Effect of F035 and F060 control on DMBA-induced hyperplasia and inflammatory response in SENCAR mouse skin
| Treatment | Dose(s) per application | Protocol
and duration of treatment
|
Epidermal hyperplasia, μm | Total dermal cellularity* | |
|---|---|---|---|---|---|
| Complete carcinogenesis | Initiation/ promotion | ||||
| Acetone | 0.2 ml | 4 wk | 13.61 ± 1.26b | 5.23 ± 1.02a | |
| DMBA | 100 nmol | 4 wk | 66.15 ± 6.62a | 27.6 ± 2.18b | |
| F035 | 0.5 mg | 4 wk | 11.74 ± 1.54b | 6.56 ± 0.89a | |
| F035 | 1.0 mg | 4 wk | 12.46 ± 2.17b | 5.92 ± 0.77a | |
| F060 | 0.5 mg | 4 wk | 11.80 ± 1.27b | 6.15 ± 1.34a | |
| F060 | 1.0 mg | 4 wk | 12.10 ± 1.38b | 6.08 ± 0.99a | |
| F035/DMBA | 0.5 mg/100 nmol | 4 wk | 24.87 ± 5.35c | 8.16 ± 1.28a | |
| F035/DMBA | 1.0 mg/100 nmol | 4 wk | 22.75 ± 4.61c | 7.81 ± 0.79a | |
| F060/DMBA | 0.5 mg/100 nmol | 4 wk | 65.04 ± 8.43a | 22.4 ± 1.89b | |
| F060/DMBA | 1.0 mg/100 nmol | 4 wk | 60.58 ± 12.2a | 23.6 ± 2.26b | |
| DMBA/TPA | 10 nmol 1 ×/2 μg | 8 wk | 67.22 ± 2.23a | 26.1 ± 3.08b | |
| DMBA/F035/TPA | 10 nmol 1 × 0.5 mg/2 μg | 8 wk | 33.56 ± 7.20c | 9.34 ± 0.68a | |
| DMBA/F035/TPA | 10 nmol 1 × 1.0 mg/2 μg | 8 wk | 28.08 ± 3.41c | 5.34 ± 0.68a | |
| DMBA/F060/TPA | 10 nmol 1 × 0.5 mg/2 μg | 8 wk | 66.69 ± 2.93a | 28.1 ± 1.88b | |
| DMBA/F060/TPA | 10 nmol 1 × 1.0 mg/2 μg | 8 wk | 65.65 ± 4.52a | 29.6 ± 2.08b | |
| Acetone | 0.2 ml | 8 wk | 10.47 ± 0.53b | 5.12 ± 0.56a | |
Values marked with the same letter are not significantly different from each other. DMBA (10 nmol, once) did not cause hyperplasia or inflammation; TPA alone gave a response similar to that of DMBA/TPA (data not shown).
*
Total dermal cellularity is a measure of inflammatory response.